Yesterday, I couldn’t stand being inside my skin. It felt like a prison, this body of mine that didn’t know what it wanted or why it was here. I squirmed through the day, fussing and eating and eating ...
FDA approves evidence-based tool (Bysanti) to address severe mood and psychotic symptoms, which may predict future indications.
Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression ...
Credit: Getty Images. Lumateperone 42mg given once daily met the primary endpoint in the study. Lumateperone monotherapy was associated with significant improvement of major depressive episodes in ...
The biopharmaceutical company said Friday Bysanti tablets were approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of ...
An antipsychotic approved by the FDA in 2009 to treat schizophrenia has now been green-lighted for use in bipolar 1 disorder. Iloperidone (Fanapt) is now FDA-approved for adults with bipolar 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results